Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection

Journal of Surgical Oncology

Volumn 100, Issue 8, 2009, Pages 736-743

  Tsai, Hsiang Lin ^a,b,c   Chu, Koung Shing ^a,d   Huang, Yu Ho ^d   Su, Yu Chung ^a,d   Wu, Jeng Yih ^a,d   Kuo, Chao Hung ^c,d   Chen, Chao Wen ^a   Wang, Jaw Yuan ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; Postoperative early relapse; Predicting factors; UICC stage I III

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CORRELATION ANALYSIS; FOLLOW UP; HUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RECTUM CANCER; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 73449098934     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21404     Document Type: Article

References (37)

1. Weitz J, Koch M, Debus J, et al.: Colorectal cancer. Lancet 2005;365:153-165.
2. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Kotake K, Honjo S, Sugihara K, et al.: Changes in colorectal cancer during a 20-year period: An extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003;46:32-43.
4. Department of Health: Cancer registry annual report, Taiwan, R.O.C. 2008. Department of Health, the Executive Yuan, Taipei, ROC, 2008.
5. OConell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425.
6. Korner H, Soreide K, Stokkeland PJ, et al.: Systematic follow-up after curative surgery for colorectal cancer in Norway: A population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005;9:320-328.
7. Walter EL, Frank EJ: The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg Clin N Am 2002;82:1091-1108.
8. Michael JO, Megan EC, Richard MG, et al.: Survival following recurrence in stage II and III colon cancer: Findings from the ACCENT data set. J Clin Oncol 2008;26:2336-2341.
9. De Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
10. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
11. Douillard JY, Cunningham D, Roth D, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000;355:1041-1047.
12. Nelson H, Petrelli N, Carlin A. et al.: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-596.
13. Huang MY, Fang WY, Lee SC, et al.: ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in highrisk stage II and stage III colorectal cancer patients. BMC Cancer 2008;12:50-62.
14. Gasser M, Gerstlauer C, Grimm M, et al.: Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer. Ann Surg Oncol 2007;14:1272-1284.
15. Lipska L, Visokai V, Levy M, et al.: Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Res 2007;27:1901-1906.
16. Tsai HL, Yeh YS, Yu FJ, et al.: Predicting factors of postoperative relapse in T2-4N0M0 colorectal cancer patients via harvesting a minimum of 12 lymph nodes. Int J Colorectal Dis 2009;24:177-183.
17. Tsai HL, Cheng KI, Lu CY, et al.: Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection. J Surg Oncol 2008;97:383-387.
18. Kobayashi H, Mochizuki H, Sugihara K, et al.: Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study. Surgery 2007;141:67-75.
19. McCall JL, Black RB, Rich CA, et al.: The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994;37:875-881.
20. Fujita S, Shimoda T, Yoshimura K, et al.: Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003;84:127-131.
21. Tsai HL, Lu CY, Hsieh JS, et al.: The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. J Gastrointest Surg 2007;11:660-665.
22. Durante AP, Bromberg SH, Barreto E, et al.: Prognostic value of lymphatic vessel and neural invasion in colorectal carcinoma. Rev Assoc Med Bras 2004;50:21-26.
23. Shiono S, Ishii G, Naqai K, et al.: Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005;79:278-282.
24. Bayar S, Saxena R, Emir B, et al.: Venous invasion may predict lymph node metastasis in early rectal cancer. Eur J Surg Oncol 2002;28:413-417.
25. Meguerditchian AN, Bairati I, Lagace R, et al.: Prognostic significance of lymphovascular invasion in surgically cured rectal carcinoma. Am J Surg 2005;189:707-713.
26. Khankhanian N, Mavligit GM, Russell WO, et al.: Prognostic significance of vascular invasion in colorectal cancer of Dukes' B class. Cancer 1977;39:1195-1200.
27. Ueno H, Hase K, Mochizuki H: Criteria for extramural perineural invasion as a prognostic factor in rectal cancer. Br J Surg 2001; 88:994-1000.
28. Davis NS, Newland RC: Terminology and classification of colorectal adenocarcinoma: The Australian clinicopathological staging system. Aust N Z J Surg 1983;53:211-221.
29. Ishizuka D, Shirai Y, Sakai Y, et al.: Colorectal carcinoma liver metastases: Clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen19-9 levels. Int J Colorectal Dis 2001;16:32-37.
30. Holubee L, Jr., Topolcan O, Pikner R, et al.: Criteria for the selection of referential groups in tumor marker statistical evaluation on the basis of a retrospective study. Anticancer Res 2003;23:856-870.
31. Chapman MA, Buckley D, Henson DB, et al.: Preoperative carcinoembryonic antigen is related to tumor stage and long-term survival in colorectal cancer. Br J Cancer 1998;78:1346-1349.
32. Longo WE, Johnson FE: The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg Clin North Am 2002;82:1091-1108.
33. Wang JY, Lu CY, Chu KS, et al.: Prognostic significance of perand post-operative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 2007;39:245-250.
34. Park YA, Lee KY, Kim NK, et al.: Prognostic effect of perioperative change of serum carcinoembryonic antigen level: A useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol 2006;13:645-650.
35. Kaiser AM, Kang JC, Chan LS, et al.: The prognostic impact of the time interval to recurrence for the mortality in recurrent colorectal cancer. Colorectal Dis 2006;8:696-703.
36. Uen YH, Lu CY, Tsai HL, et al.: The persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 2008;15:2120-2128.
37. Wang JY, Lin SR, Wu DC, et al.: Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum CEA levels. Clin Cancer Res 2007;13:2406-2413.